

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Daiichi Sankyo Launches New Generic Drugs Through Its Daiichi Sankyo Espha Subsidiary

Tokyo, Japan (June 16, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that on June 17, 2016, its generics subsidiary, Daiichi Sankyo Espha, will launch eleven new generic drugs with four new active ingredients, which have been notified through today’s official gazette.

Overview

1. Product Names/Therapeutic Categories

Product name	Therapeutic category	Original brand name
Olanzapine Tablets 2.5mg “DSEP”	Antipsychotic	Zyprexa [®] Tablets 2.5mg, 5mg, 10mg Zyprexa [®] Fine Granule 1% Zyprexa Zydis [®] Tablets 2.5mg, 5mg, 10mg
Olanzapine Tablets 5mg “DSEP”		
Olanzapine Tablets 10mg “DSEP”		
Olanzapine Fine Granule 1% “DSEP”		
Olanzapine OD Tablets 2.5mg “DSEP”		
Olanzapine OD Tablets 5mg “DSEP”		
Olanzapine OD Tablets 10mg “DSEP”		
Voriconazole Tablets 50mg “DSEP”	Systemic mycoses therapy	Vfend [®] Tablets 50mg, 200mg
Voriconazole Tablets 200mg “DSEP”		
Sertraline Tablets 100mg “DSEP”	Selective serotonin reuptake inhibitor	J Zoloft [®] Tablets 100mg
Losarhyd [®] Combination Tablets HD “EP”	ARB/diuretic combination	Preminent [®] Combination Tablets HD

*Sertraline Tablets 100mg “DSEP” and Losarhyd[®] Combination Tablets HD “EP” are additional strengths for the same compounds currently on the market.

2. Product Attributes – Daiichi Sankyo Espha Measures

Daiichi Sankyo Espha has maintained a level of quality based on the quality management standards of the Daiichi Sankyo Group to meet the various needs of patients and health care professionals. Daiichi Sankyo Espha provides innovative high value-added generic drugs with formulation and labeling which make drugs easier for patients to ingest and harder to mistakenly or incorrectly take. It also provides authorized generics which are manufactured from the same substances and additives that are manufactured in the same manufacturing methods as original drugs.


Innovative design of Press Through Package (PTP) Sheets and Tablets

Ongoing innovations in formulation and labeling reduce the burden on pharmacists when confirming and preventing drug error and prevent medical error, such as patients taking the wrong medicine or confusing one medicine for another.

- Easily recognizable original symbols:

PTP sheets feature original symbols based on formulation and disease characteristics.

Olanzapine Tablets 10mg “DSEP” and Voriconazole Tablets 50mg “DSEP” original symbols




- Other PTP sheet innovations:

To reduce drug error, PTP sheets include GS1 codes on the back of each tablet sheet. Pitch control is used to print product names and strength in same position on the PTP sheet for each tablet, making displayed content easier to read.

GS1 Code

A barcode in use as a global standard since 2010, enabling management of product attributes, such as product name, strength, lot number, and shelf life information.

Olanzapine OD Tablets 5mg “DSEP” PTP sheet



- Double-sided printing (Laser and ink-jet printing):

Double-sided Printing of Product Name, Strength for Easier Identification.

Olanzapine Tablets 5mg “DSEP”

Olanzapine OD Tablets 5mg “DSEP”



*Laser double-sided printing
Same design on both sides



*Inkjet double-sided printing
Same design on both sides

Voriconazole Tablets 50mg “DSEP” 200mg Tablets “DSEP”



*Inkjet double-sided printing with same design on both sides

Innovative Box Design — Introducing the Newly Designed “iPackage” Box

- Newly devised box display allows pharmacists to identify a variety of information.

Olanzapine Tablets 2.5mg “DSEP” individual boxes

Product information card

Detachable product information card can be used as product shelf label (product name, QR code).

QR code


Scanning QR code displays the latest package insert.

GS1 code

GS1 code includes product name, active ingredient, lot number, shelf life information.

Tablet image

This allows pharmacist to confirm tablet appearance before opening box.



About Daiichi Sankyo Espha

Daiichi Sankyo Espha manufactures and markets generic drugs and accommodates rising demand based on the spirit of the Daiichi Sankyo Group corporate philosophy* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

*Daiichi Sankyo Group corporate philosophy

To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.

Daiichi Sankyo Espha Company Overview

Company name: Daiichi Sankyo Espha Co., Ltd.

Established: April 1, 2010

Business: Manufacture and sale of pharmaceuticals

Capital: 450 million yen

Representative: President Hiroto Yoshiwaka

Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo